Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H15N3O4 |
Molecular Weight | 253.2545 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)OCC1=CC=CC(COC(=O)NC)=N1
InChI
InChIKey=YEKQSSHBERGOJK-UHFFFAOYSA-N
InChI=1S/C11H15N3O4/c1-12-10(15)17-6-8-4-3-5-9(14-8)7-18-11(16)13-2/h3-5H,6-7H2,1-2H3,(H,12,15)(H,13,16)
DescriptionSources: http://www.medoteka.ru/components/pyricarbateCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/213636
Sources: http://www.medoteka.ru/components/pyricarbate
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/213636
Parmidin (pyridinol carbamate) is a Soviet drug, has anti-arteriosclerotic (increased vascular resistance) activity, reduces the permeability of blood vessels, it helps to restore disturbed microcirculation in pathological processes. This is mainly due to the influence on kinin system, especially with a decrease in the activity of bradykinin receptors. It also reduces the aggregation of platelets. It’s used to treat: the brain vascular atherosclerosis, heart, limbs; diabetic retinopathy (non-inflammatory lesion of the retina associated with increased levels of sugar in the blood); thrombosis (violation of patency) retinal vein; occlusive disease (inflammation of the inner lining of arteries with a decrease in their lumen); trophic leg ulcers (slow-healing skin defects caused by malnutrition). Ointment is used in neurodermatitis (skin disease caused by disturbance of the central nervous system), Lichen sclerosus (teardrop scleroderma) genital organs of children, as well as a prophylactic and therapeutic agent against radiation skin lesions.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4308 Sources: DOI: 10.1007/BF00776332 Tugusheva, N.Z., Ershov, L.V., Granik, V.G. et al. Pharm Chem J (1986) 20: 483. doi:10.1007/BF00776332 |
|||
Target ID: CHEMBL3157 Sources: DOI: 10.1007/BF00776332 Tugusheva, N.Z., Ershov, L.V., Granik, V.G. et al. Pharm Chem J (1986) 20: 483. doi:10.1007/BF00776332 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Parmidin tablets 0,25 g Approved UseAtherosclerosis of vessels of the brain, heart, limbs, eyes (comprehensive treatment and prevention). |
|||
Palliative | Parmidin Approved UseUnknown |
|||
Palliative | Parmidin Approved UseUnknown |
|||
Palliative | Parmidin Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.rlsnet.ru/tn_index_id_11562.htm
Curator's Comment: http://www.piluli.kharkov.ua/drugs/drug/531/
Oral: 0.25-0.75 g 3-4 times/day. The course: 2-6 months.
Topical:- 2-3 times a day for 10-12 days
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/772874
Unknown
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29703
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB10164MIG
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | |||
|
5011
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | |||
|
C152114
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | |||
|
100000080866
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | |||
|
217-538-9
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | |||
|
4990
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL1620144
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | |||
|
D011727
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | |||
|
m9358
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID5045708
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | |||
|
2329
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | |||
|
81R511UV73
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | |||
|
1882-26-4
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | |||
|
8997
Created by
admin on Fri Dec 15 17:32:17 GMT 2023 , Edited by admin on Fri Dec 15 17:32:17 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY